Hyaluronic acid pharma manufacturer with 60+ years of R&D and global reach
Fidia Pharma is a €510M+ Italian pharma manufacturer specializing in hyaluronic acid (HA) across eye care, joint care, skin care, and wellness—distributed through 120+ countries via subsidiaries and partners. The hiring mix is heavily sales-weighted (nearly half of open roles), paired with acute pain around medical representative network strength and joint care sales growth, indicating a sales-execution gap rather than a product problem. Active projects span equipment qualification, procurement strategy, and group-wide process improvement, suggesting operational maturity focused on compliance and cost discipline rather than innovation velocity.
Fidia manufactures and distributes pharmaceutical and specialty care products centered on naturally derived and functionalized hyaluronic acid formulations. The company operates across five continents through wholly owned subsidiaries in nine countries (USA, Germany, Austria, Spain, France, Russia, Czech Republic, Poland, Romania, Egypt, Middle East, Turkey) and local distribution partnerships. With over 1,700 employees and a turnover exceeding €510 million in 2024, roughly half generated internationally, Fidia combines in-house R&D (supported by ~1,200 patents), manufacturing, and direct sales infrastructure. The product portfolio spans ophthalmology (eye care), orthopedics (joint care), dermatology (skin care), and nutritional wellness segments, positioning the company as a vertically integrated specialty pharma operator with both branded and OTC reach.
Hyaluronic acid formulations across eye care, joint care, skin care, and health & wellness. The company holds ~1,200 patents and draws on over 60 years of R&D in HA production and functionalization.
Headquartered in Abano Terme, Italy. The company has over 1,700 global employees and is privately held with 1,001–5,000 staff.
Other companies in the same industry, closest in size